Pharma

Your Article Summary

See Latest Articles

Human genome sciences announces third quarter 2009 financial results and key developments
Human Genome Sciences, 10/30/09

Human Genome Sciences, Inc. announced financial results for the quarter ended September, 2009, and provided highlights of recent key developments. “In the third quarter, we made outstanding progress on the path to commercialization of our late–stage products and substantially improved our financial strength,” said H. Thomas Watkins, President and Chief Executive Officer. “The positive Phase 3 results we have seen for both BENLYSTA for systemic lupus and ZALBIN for chronic hepatitis C suggest that each of these products represents a significant therapeutic and commercial opportunity. Assuming the second Phase 3 trial of BENLYSTA is successful, we believe it could become the first new drug approved for lupus in more than 50 years.”

Today in Financial Reports...keeping you current

Receive free subspecialty "5-minute updates" via email

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

CPSI Profits Down, Revenue Up
HealthDataManagement, 11/02/09

Ultrasound, nuc med on the upswing
Canadian Healthcare Technology, 10/16/09

See All of Financial Reports